Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41616 | 1.00 | MMP1 (0.43) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL8228297 | 0.85 | MMP1 (0.45) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL27458824 | 0.84 | MMP1 (0.44) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL1897993 | 0.82 | MMP1 (0.41) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL28311881 | 0.82 | MMP1 (0.43) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL5679261 | 0.81 | DPP8 (0.40) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL29159324 | 0.81 | MMP1 (0.40) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL10670691 | 0.81 | SLC1A3 (0.42) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL7620751 | 0.80 | SLC15A1 (0.37) | MMP1MMP2MMP9MMP12ALOX5 | |
| SCHEMBL2009145 | 0.79 | MMP1 (0.41) | MMP1MMP2MMP9MMP12ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TEMPLE OTORONGO LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20210275623-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3615053-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | Temple Otorongo LLC (US) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200381-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TEMPLE OTORONGO LLC (US) | 2018-11-01 | — | — | WO | disclosed |
| US-7807629-B1 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2010-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144842-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | OPRK1, TPH1, HTR3C | MMP1 3906/4885MMP2 2958/4885MMP9 3411/4885 |
| US-20210275623-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS | TPH1, TPH2, SYMPK | MMP1 3907/4885MMP2 3166/4885MMP9 3334/4885 |
| US-11723945-B2 | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | TPH1, TPH2, SYMPK | MMP1 3907/4885MMP2 3166/4885MMP9 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.